(TSX-V:CLIP),(OTC US:CLPMF),(Other OTC:CLPMF), TORONTO, March 31, 2025 (GLOBE NEWSWIRE) — Clip Money Inc. (TSX-V: CLIP; OTCQB: CLPMF) (“Clip Money” or the “Company“), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce its financial results for the fiscal year ended December 31, 2024. The Company reported record revenue growth in […]
(NASDAQ:CGON), – Durability Results from BOND-003 data will be presented as a late breaker as part of AUA's Practice-changing, Paradigm-shifting Clinical Trials in Urology – – Additional updates from across CG Oncology's clinical trial program, including translational data, planned – IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage
(NYSE:EBS), GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026. “As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our
(NASDAQ:PHAT), For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA-approved treatment of its kind for both types of GERD1 A Media Snippet accompanying
(NASDAQ:COCP), BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “Our novel, potent antiviral compounds for norovirus, influenza and coronavirus address critical gaps
LONG BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Angels for Sight dedicated its state-of-the-art vision clinic on March 28, 2025 in Long Beach, California with community members, dignitaries and charitable partners all in attendance. Representatives from Congressman Robert Garcia, Congresswoman Nanette Diaz BarragaÌn, California State Senator Laura Richardson, Compton Mayoral and City Council representatives
(NASDAQ:ECOR), ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030. “Obtaining a follow-on contract in this macro environment
(NASDAQ:MNPR), WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments. “2024 was a productive year for Monopar, with the in-licensing of ALXN1840, the
(NYSE MKT:TOVX), ROCKVILLE, Md., March 31, 2025 (GLOBE NEWSWIRE) — Theriva(TM) Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that a second Independent Data Monitoring Committee (IDMC) review of data from the VIRAGE Phase 2b clinical trial in
(NASDAQ:KALA), — Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) — — Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 — — Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused